GDC-0068 --- Akt Inhibitor

Catalog No. size PriceQuantity
M60066-5S 5mg solid $159
M60066-50S 50 mg solid $1,060


GDC-0068 is a highly potent, selective, and orally available pan-Akt inhibitor, targeting Akt1, Akt2 and Akt3 with IC50 of 5 nM, 18 nM and 8 nM, respectively. It has >100-fold selectivity over a broad panel of 230 kinases, except PRKG1α and PRKG1β with IC50 of 98 nM and 69 nM. GDC-0068 can effectively block Akt signaling and induce cell cycle arrest in human cancer cell lines in vitro, and exhibit significant efficacy in PTEN- and PI3K mutant xenograft models, including PTEN-deficient prostate cancer models LNCaP and PC3, the PIK3CA H1047R mutant breast cancer model KPL-4, and MCF7-neo/HER2 tumor model. A Phase I study of GDC-0068 in patients with refractory solid tumors is ongoing.

Product information

CAS Number: 1001264-89-6

Molecular Weight: 458.00

Formula: C24H32ClN5O2



Chemical Name: (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one

Smiles: CC(C)NC[C@H](C1=CC=C(Cl)C=C1)C(=O)N1CCN(CC1)C1=NC=NC2[C@H](O)C[C@@H](C)C=21


InChi: InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO up to 100 mM

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

GDC-0068 was used at 5-10 µM final concentration in vitro and in cellular assays.

In Vivo:

GDC-0068 was orally dosed to mice at 50-100 mg/kg once per day, or in combination with MEK inhibitors or chemotherapy agents to significantly reduce the tumor volume. Formulation: 0.5% methylcellulose/0.2% Tween-80.


  1. Blake JF, et al. Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors. (2012) J Med Chem. 55(18):8110-27.
  2. Heidi M, et al. Abstract 966: Predictive biomarkers of the AKT inhibitor, GDC-0068, in single agent and combination studies. (2012) Cancer Research. Volume 72, Issue 8, Supplement 1
  3. Kui Lin. Abstract DDT02-01: GDC-0068: A novel, selective, ATP-competitive inhibitor of Akt. (2011) Cancer Research. Volume 71, Issue 8, Supplement 1

Products are for research use only. Not for human use.


Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed